Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000058712) titled 'Therapeutic Option for Nintedanib related diArrhea in patients with progressive fibrosing interstitial lung disease a multicenter Clinical triAl' on Aug. 6.
Study Type: Interventional
Study Design:
Parallel Randomized
Primary Sponsor: Shinmatsudo central general Hospital
Condition:
Patients with PF-ILD, excluding scleroderma
Intervention:
After onset of nintedanib-associated diarrhea, nintedanib dose was reduced (nintedanib 150 mg twice a day in the morning and evening is reduced to 100 mg twice a day).
After onset of nintedanib-associated diarrhea, MIYA BM (two MIYA BM tablets three times a day after br...